GlycoMimetics

GlycoMimetics is a late clinical-stage biotechnology company focused on developing glycobiology-based therapies for cancers and inflammatory diseases. Their innovative approach leverages a deep understanding of the role carbohydrates play in cell recognition. They utilize a proprietary chemistry platform to develop small molecule drugs, known as glycomimetics, which alter carbohydrate-mediated recognition in various disease states. GlycoMimetics prioritizes advancing their wholly-owned drug candidates through research and late-stage clinical development. Their lead molecule, uproleselan, is currently in pivotal Phase 3 development for people with relapsed/refractory AML. Uproleselan has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration, demonstrating its promising potential.

GlycoMimetics is headquartered in Rockville, MD, and is committed to developing treatments that provide hope for patients. They are a team of passionate, creative individuals dedicated to making a difference in the lives of those living with difficult-to-treat diseases. The company offers competitive benefits, including health and dental plans, a 401K with an employer match, paid time off, and the opportunity to participate in company equity. GlycoMimetics is an equal opportunity employer, striving to create a diverse and inclusive work environment.

GlycoMimetics offers a flexible work environment, including a Telework Program that allows employees to work remotely, and a paid medical-parental leave program for those with new additions to their family. While specific details on flexible work arrangements are not explicitly stated, the company emphasizes a desire to attract and retain talented individuals, which suggests an openness to discussions about individual needs and preferences.

GlycoMimetics offers a comprehensive benefits package to its full-time employees, including competitive salaries, 401(k) with employer match, health and dental insurance, vision care, paid time off, paid holidays, flexible spending accounts, life insurance, disability coverage, and supplemental insurance options. In addition, employees can participate in the company's stock option plan, performance bonus program, telework program, tuition reimbursement program, and fitness center/wellness program.

GlycoMimetics is a late clinical-stage biotechnology company dedicated to discovering and developing innovative glycobiology-based therapies for cancers and inflammatory diseases. Their mission is to improve patient outcomes by leveraging their deep understanding of carbohydrates and their role in cell recognition, utilizing their proprietary chemistry platform to discover small molecule drugs known as glycomimetics. These drugs alter carbohydrate-mediated recognition in diverse disease states, pushing their wholly-owned drug candidates through research and into late-stage clinical development.

GlycoMimetics promotes a culture of shared responsibility, collaboration, and trust. They value the expertise and experience of their team members, creating an environment where everyone is expected to contribute and listen. They operate with integrity, honoring commitments and striving for mastery in everything they do. This foundation of respect and accountability guides their actions, conversations, and decisions, all in service of advancing the care of patients with cancer and inflammatory diseases.

GlycoMimetics is committed to fostering a diverse, equitable, and inclusive workplace, recognizing the value of a diverse workforce in driving innovation and achieving its mission. The company emphasizes creating a collaborative, open working environment where all team members feel valued, respected, and empowered to contribute their unique perspectives and talents. GlycoMimetics is an equal opportunity employer and prohibits discrimination based on sex, race, age, disability, religion, national origin, color, or any other protected class.